In this context, the incretin GLP1 has also been proposed as a NAFLD treatment target since it increases hepatic fatty acid oxidation and decreases lipogenesis [49], while CCK plays an important role in the uptake of TG-derived fatty acids [50] and in the regulation of bile acid, which accumulation (cholestasis) reduces liver steatosis [51]. This evidence concerns the gene GCG and fatty liver disease.